Figure 6.

Anaesthetized rats with in situ perfusion of gastric lumen. (A) Effects of irinotecan (10 μmol kg⁻¹ i.v. or 0.01 – 0.1 μmol kg⁻¹ i.c.v.), SN-38 (20 μmol kg⁻¹ i.v.) or physostigmine (3 μmol kg⁻¹ i.v.) on gastric acid secretion. (B) Effects of irinotecan (10 μmol kg⁻¹ i.v.) either alone or in the presence of bilateral cervical vagotomy, atropine (3 μmol kg⁻¹ i.v.), ondansetron (15 μmol kg⁻¹ i.v.) or capsazepine (50 μmol kg⁻¹ i.v.) on gastric acid secretion. (C) Effects of irinotecan (10 μmol kg⁻¹ i.v.) and electrical vagal stimulation, either alone or in the presence of atropine (3 μmol kg⁻¹ i.v.), on gastric acid secretion in rats subjected to systemic ablation of capsaicin-sensitive sensory nerve fibres. (D) Effects of irinotecan (10 μmol kg⁻¹ i.v.) and electrical vagal stimulation, either alone or in the presence of atropine (3 μmol kg⁻¹ i.v.), on gastric acid secretion in rats subjected to perivagal application of capsaicin. Each column represents the mean value obtained from 6 – 8 animals±s.e.mean (vertical lines). ^*P<0.05: significant difference from control values: ^aP<0.05: significant difference from irinotecan alone.